The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), today issued the following statement in response to the bipartisan passage of the Coronavirus Aid, Relief, and Economic Security Act.
The Partnership to Amend 42 CFR Part 2 (Partnership), a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), thanks Senators Capito and Manchin, along with all the other champions and co-sponsors of the Legacy Act for their tireless work and dedication to combatting the opioid epidemic.
We, as patients, consumers, taxpayers, health care providers, payers, and members of the pharmaceutical and medical device pipeline, are ready to work with The President's Administration to ensure that America’s patients and our health care system receive the treatments they need throughout this public health crisis.
These are trying times, especially for health care practitioners. Together, as managed care pharmacy professionals, we face challenges to patient care. AMCP CEO Susan A. Cantrell, RPh, CAE addresses these unique challenges in her latest blog post.
As representatives of the drug supply and payment chain, ranging from pharmaceutical manufacturers, pharmacies, specialty pharmacies, managed care pharmacy, pharmacy benefit managers (PBMs), to health plans, we are aligned on the important principle that the private sector and state and federal governments must work together to facilitate Americans’ reliable access to needed prescription drugs during the COVID-19 pandemic.
Aligning stakeholder perspectives, providing timely and meaningful drug pricing information, and establishing common definitions of health care value could help ensure patients are able to access medications they need at costs they can afford.
Our organizations are pleased to submit these comments regarding the Food and Drug Administration’s (“FDA”) proposed rule regarding wholesale importation of prescription drugs from Canada. Collectively, we represent over 200,000 pharmacists, student pharmacists, residents and pharmacy technicians in all settings.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its new Draft Guidance, “Advanced Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies – Part II” published on February 5, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its new Draft Guidance, “Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans” published in the Federal Register on February 6, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to its new Draft Guidance, “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act [FDA-2019-D-5743]” published in the Federal Register on December 23, 2019.